Sage Therapeutics stock drops
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.
Sage Therapeutics to discontinue development of Alzheimer’s drug
Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
Sage Therapeutics Phase 2 LIGHTWAVE Study In Alzheimer's Disease Fails; Stock Down In Pre-Market
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD) failed to meet the primary goal. The company's shares were down more than 12 percent in pre-market.
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD).
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares tank
Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it did not meet the main goal in a mid-stage trial, sending its shares down about 12% to $5.
Sage Therapeutics Shares Fall Premarket After Alzheimer's Setback
Sage Therapeutics shares fell more than 10% in premarket trading Tuesday after the latest setback for the biopharmaceutical company's dalzanemdor drug candidate. Shares of Sage, which closed Monday at $6.72, were recently down 12% to $5.89 in premarket trading.
Sage Therapeutics stops Alzheimer’s drug development after trial fails
Sage said it will continue to test dalzanemdor as a treatment for Huntington's disease and expects to report its mid-stage trial data later this year.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
Sage Therapeutics Ends Development of Dalzanemdor in Alzheimer's Disease
Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.
Hold Rating on SAGE Therapeutics Amid Clinical Trial Uncertainties
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...
FierceBiotech7h
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
BioSpace6h
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
Sage stock slides as RBC cuts rating to Sell on trial results concerns
RBC Capital Markets cut its rating on SAGE Therapeutics Inc (NASDAQ:SAGE) from Sector Perform to Underperform (Sell), due to ...
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: ...
Fintel on MSN3d
RBC Capital Downgrades Sage Therapeutics (SAGE)
Fintel reports that on October 4, 2024, RBC Capital downgraded their outlook for Sage Therapeutics (NasdaqGM:SAGE) from ...